Sanofi Makes Strategic Equity Investment in Zucara Therapeutics
Deal News | Nov 13, 2024 | Ropes & Gray
Sanofi, the multinational healthcare company, has made a strategic equity investment in Zucara Therapeutics, a Toronto-based diabetes-focused life sciences company. This investment forms part of Zucara's $20 million Series B financing. Zucara is developing ZT-01, a therapeutic aimed at preventing hypoglycemia in diabetic patients, and the new funds will support the completion of an ongoing Phase 2a clinical trial geared towards developing a once-weekly version of the drug. As part of the agreement, Sanofi secures an exclusive right of first negotiation for future developments. The legal advisory for Sanofi’s investment was provided by Ropes & Gray, specifically involving associates from their venture capital, emerging companies, and life sciences licensing practices.
Sectors
- Pharmaceuticals
- Biotechnology
- Venture Capital
Geography
- Canada – Zucara Therapeutics is based in Toronto, Canada, indicating where the biotech company operates.
- France – Sanofi is a French multinational pharmaceutical company based in Paris, France.
Industry
- Pharmaceuticals – The article deals with Sanofi, a multinational pharmaceutical company, making an investment in drug development through Zucara Therapeutics.
- Biotechnology – Zucara Therapeutics is involved in the development of biotechnology solutions, particularly the ZT-01 therapeutic for diabetes.
- Venture Capital – The transaction described is a part of a Series B financing round, which is a form of venture capital investment.
Financials
- $20 million – The Series B financing amount invested by Sanofi into Zucara Therapeutics.
Participants
| Name | Role | Type | Description |
|---|---|---|---|
| Sanofi | Investor | Company | Sanofi is a leading French multinational pharmaceutical company investing in Zucara Therapeutics. |
| Zucara Therapeutics | Target Company | Company | Toronto-based Zucara Therapeutics is developing diabetes treatments and is the recipient of Sanofi's investment. |
| Ropes & Gray | Legal Advisor | Company | A law firm providing legal advisory to Sanofi in the investment transaction. |
| Abigail Gregor | Life Sciences Licensing Partner | Person | A partner at Ropes & Gray involved in the Sanofi-Zucara transaction. |
| Daniel Freshman | Venture Capital & Emerging Companies and Life Sciences Licensing Associate | Person | An associate at Ropes & Gray, contributing to the legal advisory for the transaction. |
| Philip Wu | Venture Capital & Emerging Companies and Life Sciences Licensing Associate | Person | An associate at Ropes & Gray, involved in advising Sanofi. |